NL · biotech · inflammatory diseases · therapeutics
One round we have observed, with the investors the report named. Every figure below came from a named source, and where the company reported the raise to the SEC itself, that is shown beside it.
Series B · Dec 2024 · €85M
Forbion lead, Novartis Venture Fund lead, Johnson & Johnson Innovation – JJDC, Inc lead, Seventure Partners, Pureos Bioventures, BOM, BioGeneration Ventures, Citryll's founders, Curie Capital
Reported by Silicon Canals
Missing a round, or an investor who was in one? Tell us.